application for SNUG01 — a first-in-class TRIM72 (Tripartite Motif Protein 72)-targeted gene therapy candidate for amyotrophic lateral sclerosis (ALS). The clearance authorizes a global Phase I/IIa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback